Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty.

[1]  C. Gaos,et al.  Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. , 1992, Catheterization and cardiovascular diagnosis.

[2]  J. J. Ferguson.  All ACTs are not created equal. , 1992, Texas Heart Institute journal.

[3]  J. Vacek,et al.  Validation of a bedside method of activated partial thromboplastin time measurement with clinical range guidelines. , 1991, The American journal of cardiology.

[4]  R. Baugh,et al.  Heparin monitoring in the coronary care unit after percutaneous transluminal coronary angioplasty. , 1990, Heart & lung : the journal of critical care.

[5]  D. Bennett,et al.  Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. , 1990, British heart journal.

[6]  L. Klein,et al.  Adequate heparinization during PTCA: assessment using activated clotting times. , 1989, Catheterization and cardiovascular diagnosis.

[7]  S. Thomas,et al.  The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass. , 1983, The Journal of thoracic and cardiovascular surgery.

[8]  C. Kisker,et al.  Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. , 1978, The Annals of thoracic surgery.

[9]  J. Verska.  Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis. , 1977, The Annals of thoracic surgery.

[10]  R. Pifarré,et al.  Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. , 1977, The Journal of thoracic and cardiovascular surgery.

[11]  K. Mattox,et al.  Use of the activated coagulation time in intraoperative heparin reversal for cardiopulmonary operations. , 1975, The Annals of thoracic surgery.

[12]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. , 1975, The Journal of thoracic and cardiovascular surgery.

[13]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. , 1975, The Journal of thoracic and cardiovascular surgery.

[14]  C. Mielke,et al.  A simple method of heparin management during prolonged extracorporeal circulation. , 1974, The Annals of thoracic surgery.

[15]  P. Hattersley.  Activated coagulation time of whole blood. , 1966, JAMA.